Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has issued an announcement.
Oxford BioMedica PLC has reported a strong start to the fiscal year 2025, with revenues for the first half reaching £70-73 million, marking a 38%-44% increase compared to the same period in 2024. The company has secured £149 million in new orders during the first half of 2025, more than doubling the previous year’s figures, and has reiterated its full-year revenue guidance of £160-170 million. The company’s multi-vector, multi-site strategy is progressing well, with increased demand for its services and a strong order book providing confidence in future growth. OXB is expanding its manufacturing and development capacity to meet growing demand, particularly in late-stage lentiviral programs, and is enhancing its global operations to support clients across various geographies and development stages.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s strong corporate events and positive technical indicators are somewhat offset by weak financial performance and valuation concerns. The company’s strategic initiatives and market position provide a positive outlook, but financial stability remains a key risk.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB offers a range of services from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise. The company is headquartered in Oxford, UK, with facilities in the UK, France, and the US.
YTD Price Performance: -8.81%
Average Trading Volume: 143,942
Technical Sentiment Signal: Buy
Current Market Cap: £406.5M
See more insights into OXB stock on TipRanks’ Stock Analysis page.